FOLH1 and prostate carcinoma: Besides, the development of radiopharmaceutical therapy for prostate cancer base on the labeled antibodies such as 225Ac-PSMA-617, 177Lu/225Ac-J591, 255Ac/90Y-hu5A10, 177Lu-SC16, 225Ac-YS5 for preclinical application on prostate cancer were evaluated17, but it is not currently available in Vietnam because imports are expensive.